Showing results (121-130 of 311) with videos related to
Sort By:
Pageof 32
American Journal of Clinical Oncology|October 1, 1985
A phase II study of bisantrene in advanced refractory breast cancer. An Eastern Cooperative Oncology Group pilot studyK J Pandya, F M Muggia, R T Skeel, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 5, 2003
Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactionsA Chanan-Khan, J Szebeni, S Savay, et al.Cancer Treatment Reports|November 1, 1979
Analysis and interpretation of response rates for anticancer drugsY J Lee, R Catane, M Rozencweig, et al.Cancer|July 1, 1988
Toxicity comparisons between two chemotherapy regimens as adjuvant or salvage treatment in nonseminomatous testicular cancerR B Weiss, D M Stablein, F M Muggia, et al.Anti-Cancer Drugs|July 19, 2001
Phase I and pharmacologic study of i.v. hydroxyurea infusion given with i.p. 5-fluoro-2'-deoxyuridine and leucovorinA A Garcia, F M Muggia, C P Spears, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 1, 1992
Intraperitoneal therapy for ovarian cancer: analysis of fluid distribution by computerized tomographyF M Muggia, E LePoidevin, S Jeffers, et al.Gynecologic Oncology|August 1, 1997
Phase I/II study of intraperitoneal floxuridine and platinums (cisplatin and/or carboplatin)F M Muggia, S Jeffers, L Muderspach, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 31, 1998
Cellular but not plasma pharmacokinetics of lometrexol correlate with the occurrence of cumulative hematological toxicityT W Synold, E M Newman, M Carroll, et al.Cancer Research|August 15, 1990
Role of (+-)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) in modulating free radical scavenging enzymes in doxorubicin-induced cardiomyopathyP Alderton, J Gross, M D GreenInvestigational New Drugs|April 1, 1992
Phase II study of 10-EdAM in patients with squamous cell carcinoma of the head and neck, previously untreated with chemotherapyM D Green, P Sherman, J ZalcbergPageof 32